Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)’s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)’s results – MS Wkly

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), both competing one another are Biotechnology companies. We will compare their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

In table 1 we can see Brainstorm Cell Therapeutics Inc. and Pieris Pharmaceuticals Inc.s top-line revenue, earnings per share and valuation.

Profitability

Table 2 represents Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)s return on equity, return on assets and net margins.

Volatility & Risk

A beta of 1.19 shows that Brainstorm Cell Therapeutics Inc. is 19.00% more volatile than Standard and Poors 500. Competitively, Pieris Pharmaceuticals Inc.s 21.00% volatility makes it more volatile than Standard and Poors 500, because of the 1.21 beta.

Liquidity

Brainstorm Cell Therapeutics Inc.s Current Ratio and Quick Ratio are 1 and 1 respectively. The Current Ratio and Quick Ratio of its competitor Pieris Pharmaceuticals Inc. are 3 and 3 respectively. Pieris Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Brainstorm Cell Therapeutics Inc.

Analyst Ratings

The Recommendations and Ratings for Brainstorm Cell Therapeutics Inc. and Pieris Pharmaceuticals Inc. are featured in the next table.

Brainstorm Cell Therapeutics Inc. has a consensus target price of $9, and a 140.00% upside potential. Competitively Pieris Pharmaceuticals Inc. has a consensus target price of $5, with potential upside of 45.77%. The data from earlier shows that analysts view suggest that Brainstorm Cell Therapeutics Inc. seems more appealing than Pieris Pharmaceuticals Inc.

Insider and Institutional Ownership

The shares of both Brainstorm Cell Therapeutics Inc. and Pieris Pharmaceuticals Inc. are owned by institutional investors at 11.4% and 61.7% respectively. About 0.6% of Brainstorm Cell Therapeutics Inc.s share are held by insiders. On the other hand, insiders held about 0.23% of Pieris Pharmaceuticals Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc. has weaker performance than Pieris Pharmaceuticals Inc.

Summary

On 8 of the 11 factors Pieris Pharmaceuticals Inc. beats Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases. It has strategic partnership agreements with Allergan, Inc.; Sanofi Group; Daiichi Sankyo Company Limited; F.Hoffmann- La Roche Ltd. and Hoffmann- La Roche Inc.; ASKA Pharmaceutical Co., Ltd; and Les Laboratoires Servier and Institut de Recherches Internationales. The company also has a research and licensing agreement with Technische Universitt Mnchen; and a collaboration agreement with AstraZeneca. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more here:
Reviewing Brainstorm Cell Therapeutics Inc. (BCLI)'s and Pieris Pharmaceuticals Inc. (NASDAQ:PIRS)'s results - MS Wkly